Oct 28, 2026, 1:35 PM
BF Biosciences certifies resolutions passed at its 2026 AGM
AGM / EGMBF Biosciences Limited issued a certified extract of resolutions passed at its Annual General Meeting held on 28 October 2026. Shareholders confirmed the prior AGM minutes, adopted the audited financial statements for the year ended 30 June 2026, appointed KPMG Taseer Hadi & Co. as auditors for the year ending 30 June 2027, and approved related-party transactions conducted in 2025–26 as well as authorization for future related-party transactions.
Key Findings
- The Annual General Meeting was held on 28 October 2026.
- The audited financial statements for the year ended 30 June 2026 were approved and adopted.
- KPMG Taseer Hadi & Co. was re-appointed as auditor for the year ending 30 June 2027; remuneration is as recommended and approved by the Board.
- Related-party transactions conducted during financial year 2025–26 were ratified, and the Board was authorized to approve future related-party transactions.
Meeting Details
Meeting
Annual general meeting
Date
Oct 28, 2026, 12:00 AM
Meeting Details
Agenda
- Confirm minutes of the Annual General Meeting held on 25 October 2025.
- Receive, consider and adopt the audited financial statements for the year ended 30 June 2026, together with the Chairman’s Review, Directors’ Report and Auditors’ Report.
- Appoint auditors for the year ending 30 June 2027 and fix their remuneration.
- Approve related-party transactions conducted during financial year 2025–26 and authorize the Board to approve future related-party transactions.
Resolutions
- Confirmed the minutes of the Annual General Meeting held on 25 October 2025.
- Approved and adopted the audited financial statements for the year ended 30 June 2026, together with the Chairman’s Review, Directors’ Report and Auditors’ Report.
- Re-appointed KPMG Taseer Hadi & Co. as auditors for the year ending 30 June 2027, with remuneration as recommended and approved by the Board.
- Ratified and confirmed related-party transactions conducted during financial year 2025–26 and authorized the Company to enter into related-party transactions as considered fit and approved by the Board.
⚡
Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.